These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38601762)

  • 1. Impact of the Coronavirus Disease 2019 pandemic on neoadjuvant chemotherapy use in patients diagnosed with epithelial type ovarian cancer.
    Mukherjee A; Shammas N; Xu L; Cannavale KL; Gilfillan AD; Szamreta EA; Monberg M; Hodeib M; Chao CR
    Front Oncol; 2024; 14():1290719. PubMed ID: 38601762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI
    Gynecol Oncol; 2016 Oct; 143(1):3-15. PubMed ID: 27650684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.
    Liu YL; Zhou QC; Iasonos A; Filippova OT; Chi DS; Zivanovic O; Sonoda Y; Gardner G; Broach V; OCearbhaill R; Konner JA; Aghajanian CA; Long K; Tew W
    Int J Gynecol Cancer; 2020 Oct; 30(10):1554-1561. PubMed ID: 32522770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. African American women with advanced-stage ovarian cancer have worse outcomes regardless of treatment type.
    Whitmore G; Ramzan A; Sheeder J; Guntupalli SR
    Int J Gynecol Cancer; 2020 Jul; 30(7):1018-1025. PubMed ID: 32107316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the COVID-19 Pandemic on Diagnosis and Management of Gynecological Cancer: A Single-Center Analysis.
    Antunes D; Mendonça L; Melo Â; Gonçalves S; Nogueira Martins F; Nogueira Martins N
    Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor Analysis of Health Care Access With Ovarian Cancer Surgery and Gynecologic Oncologist Consultation.
    Gupta A; Chen Q; Wilson LE; Huang B; Pisu M; Liang M; Previs RA; Moss HA; Ward KC; Schymura MJ; Berchuck A; Akinyemiju TF
    JAMA Netw Open; 2023 Feb; 6(2):e2254595. PubMed ID: 36723938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The "collateral damage" of the war on COVID-19: impact of the pandemic on the care of epithelial ovarian cancer.
    Goenka L; Anandaradje A; Nakka T; Kayal S; Dubashi B; Chaturvedula L; Veena P; Durairaj J; Penumadu P; Ganesan P
    Med Oncol; 2021 Sep; 38(11):137. PubMed ID: 34581889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
    Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
    Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.
    Letourneau JM; Sinha N; Wald K; Harris E; Quinn M; Imbar T; Mok-Lin E; Chien AJ; Rosen M
    Hum Reprod; 2017 Oct; 32(10):2123-2129. PubMed ID: 28938748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
    Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
    JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the COVID-19 Pandemic on Breast Cancer Stage at Diagnosis, Presentation, and Patient Management.
    Tonneson JE; Hoskin TL; Day CN; Durgan DM; Dilaveri CA; Boughey JC
    Ann Surg Oncol; 2022 Apr; 29(4):2231-2239. PubMed ID: 34812981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer.
    Melamed A; Rauh-Hain JA; Gockley AA; Nitecki R; Ramirez PT; Hershman DL; Keating N; Wright JD
    JAMA Oncol; 2021 Dec; 7(12):1782-1790. PubMed ID: 34591081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Proportion of Patients with Bone and Soft Tissue Tumors Contracted Coronavirus-19 and Died From Surgical Procedures During the Initial Period of the COVID-19 Pandemic? Results From the Multicenter British Orthopaedic Oncology Society Observational Study.
    Rajasekaran RB; Ashford RU; Cosker TDA; Stevenson JD; Jeys L; Pollock R; Rankin KS; Cool P; Patton JT; Whitwell D; Gibbons CLMH; Carr A;
    Clin Orthop Relat Res; 2021 May; 479(5):1158-1166. PubMed ID: 33196585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
    Algera MD; van Driel WJ; Slangen BFM; Kruitwagen RFPM; Wouters MWJM;
    Gynecol Oncol; 2022 May; 165(2):330-338. PubMed ID: 35221132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment delay and treatment pattern modifications among epithelial ovarian cancer patients during the COVID-19 pandemic: A retrospective cohort study.
    Moterani VC; Moterani NJW; Candido Dos Reis FJ
    J Surg Oncol; 2022 Dec; 126(7):1155-1161. PubMed ID: 35929947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.